Hangover Joes Recovery Shot Continues Global Expansion

Hangover Joes (HJOE)

Hangover Joe’s (OTCBB: HJOE) The Hangover Recovery Shot, an official licensed product of “The Hangover” movie, continues to experience broadened distribution domestically and abroad.  The company said this morning that the two-ounce hangover helper will be available via distribution partner RAGE Beverages, Inc. in Canada and A 2 Trade Partners in Australia and New Zealand by the end of September.

The product is designed to give the over 130 million people in the U.S. each month with hangovers a way to overcome the day-after side effects of alcohol consumption.

The Hangover Recover Shot is a currently being sold in major chains like 7-Eleven and smaller independent shops and readily available to prospective convenience stores through U.S. vendors McLane Company, Inc. and Core-Mark.  The recovery shot, comprised of a unique blend of antioxidants, vitamins and herbs, has received a four-star rating from industry expert BevNET.

“Unlike other recovery shots that are made with ingredients you can barely pronounce or leave a bad taste in your mouth, our recovery shot tastes great and consists of natural ingredients like green tea leaf, acai fruit extracts, goji berry concentrate and vitamins B6 and B12,” said Hangover Joe’s co-founder Mike Jaynes.

Hangover Joe’s (HJOE) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Tyson Chandler Joins Growing Team of Superstars at Fuse Science

Tyson Chandler Joins Growing Team of Superstars at Fuse Science(0)

Getting stars to endorse a product is a big advantage in marketing.  After all, there’s a good reason that Citizen has Super Bowl MVP Eli Manning, two-time Daytona 500 winner Matt Kenseth and 2010 U.S. Women’s Open champion Paula Creamer sporting their watches and companies like Chattem, a subsidiary of Sanofi-Aventis (NYSE: SNY), get superstars

Stocks Continue Upward Path on Thursday

Stocks Continue Upward Path on Thursday(0)

U.S. stocks acquired strength Thursday on another quiet trading day, as investors parsed through a mixed bag of economic data. The Dow Jones industrial average came from behind to gain 85.53 points to 13,250.11. The S&P 500 tacked-on 9.98 points to 1,415.51. The Nasdaq added 31.46 points to 3,062.39. Cisco Systems helped fuel the rally

Stocks Mixed Again Tuesday on Strong Retail Sales

Stocks Mixed Again Tuesday on Strong Retail Sales(0)

U.S. stocks were mixed Tuesday as investors welcomed encouraging data on the U.S. economy and from the euro-zone. The Dow Jones industrial average stayed ahead 2.71 points to close at 13,172.10. The S&P 500 slipped 0.18 points to 1,403.93. The Nasdaq slid 5.54 points to 3,016.98. Investors were heartened after a government report showed that

Cortex Pharmaceuticals Expands Pipeline through Merger with Pier Pharma

Cortex Pharmaceuticals Expands Pipeline through Merger with Pier Pharma(0)

Sleep apnea, a condition in which breathing stops or gets very shallow during sleep, is a common disorder that can have serious consequences, including an increased risk of high blood pressure, heart attack and stroke.  The most common type of sleep apnea, according to the National Institute of Health, is obstructive sleep apnea, meaning that

Cardium Therapeutics Releases Excellagen Case Studies

Cardium Therapeutics Releases Excellagen Case Studies(0)

Cardium Therapeutics (NYSE MKT: CXM) has released new case study information on its Excellagen wound care management product. Excellagen is a new, highly-refined bovine Type I collagen–based topical gel designed to support favorable wound care management. Excellagen’s unique high molecular weight sterile, collagen formulation is topically applied through easy to control, pre-filled, single-use syringes. It

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.